WO2024035688A1 - Agents de dégradation de bcl6 macrocycliques - Google Patents

Agents de dégradation de bcl6 macrocycliques Download PDF

Info

Publication number
WO2024035688A1
WO2024035688A1 PCT/US2023/029714 US2023029714W WO2024035688A1 WO 2024035688 A1 WO2024035688 A1 WO 2024035688A1 US 2023029714 W US2023029714 W US 2023029714W WO 2024035688 A1 WO2024035688 A1 WO 2024035688A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
methyl
carbocyclyl
mmol
Prior art date
Application number
PCT/US2023/029714
Other languages
English (en)
Inventor
Lyn Howard Jones
Huang Huang
Yingpeng LIU
Jianwei Che
Nikki KONG
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of WO2024035688A1 publication Critical patent/WO2024035688A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • Thalidomide analogs modulate the activity of the Cullin Really Interesting New Gene (RING) ligase 4-cereblon (CRBN) (CRL4 CRBN ) E3 ubiquitin ligase to recruit and ubiquitinate neo-substrates including Ikaros family zinc finger 1 (IKZF1), IKZF3, and casein kinase 1-alpha (CK1 ⁇ ), which leads to their proteasomal degradation (Kronke et al., Science 343:301-305 (2014); Lu et al., Science 343:305-309 (2014); Kronke et al., Nature 523:183-188 (2015)).
  • IKZF1 Ikaros family zinc finger 1
  • CK1 ⁇ casein kinase 1-alpha
  • RNA binding motif protein 39 RBM39
  • DCAF15 CUL4 associated factor 15
  • Other types of small molecules that include hetero-bifunctional degraders also known as PROTACs
  • PROTACs hetero-bifunctional degraders
  • BCL6 B cell lymphoma 6
  • DLBCL diffuse large B-cell lymphomas
  • GCs germinal centers
  • AICDA DNA-editing enzyme
  • Some of these target genes control DNA damage sensing (i.e., ATR, CHEK1, TP53, ARF) and proliferation checkpoints (i.e., CDKN1A, CDKN1B, CDKN2A, CDKN2B, PTEN) (Hatzi et al., Trends Mol. Med.20:343-352 (2014)).
  • BCL6 also represses genes required for exit from the GC reaction and plasma cell differentiation (e.g., IRF4, PRDM1). This ensures that GC B cells have sufficient time to acquire somatic hyper-mutation of their immunoglobulin genes. Thus, deregulated suppression of these target genes could result in malignant transformation of B cells.
  • BCL6 also represses numerous oncogenes in GC B cells, including MYC, BCL2, BMI1, and CCND1 (Ci et al., Blood 113:5536-5548 (2009)). Through this function, BCL6 may mitigate its own pro-oncogenic checkpoint repression effect and thus reduce the potential for malignant transformation of GC B cells. This effect is abrogated in the presence of BCL2 or MYC translocations, which drive expression of these oncogenes through aberrant regulatory elements.
  • BCL6 function is terminated by the disruption of BCL6 transcriptional complexes through CD40-induced ERK signaling and downregulation of BCL6 mRNA by IRF4 and PRDM1 (Polo et al., Blood 112:644-651 (2008)). Termination of BCL6 function is required for B cells to exit the GC reaction.
  • BCL6 is a promising drug target for non-Hodgkin lymphomas such as diffuse large B cell lymphoma (DLBCL) (Cerchietti et al., Cancer Cell 17:400-411 (2010); Cardenas et al., J. Clin. Invest. 126:3351-3362 (2016)) and follicular lymphoma (Bosga-Bouwer et al., Genes Chromosomes Cancer 44:301-304 (2005)).
  • DLBCL diffuse large B cell lymphoma
  • Bosga-Bouwer et al., Genes Chromosomes Cancer 44:301-304 (2005) Pathologically increased BCL6 expression, as a result of somatic BCL6 translocation, exonic mutation, promoter mutation, or mutations in regulatory pathways, is a common driver of B cell malignancies (Hatzi et al., Trends Mol.
  • BCL6 acts as a master transcriptional repressor enabling rapid expression of germinal center (GC) B cells and tolerance to genomic instability caused by hypermutation of the immunoglobulin genes and class switch recombination (Hatzi et al., Trends Mol. Med.20:343-352 (2014)). BCL6 represses a broad range of genes involved in the DNA damage response (Ranuncolo et al., Blood Cells Mol.
  • Broad complex/Tramtrack/Bric-a-brac (BTB) proteins are a diverse family of proteins that are characterized by the presence of a common protein-protein interaction domain, known as the BTB domain.
  • BTB proteins have diverse functions ranging from transcriptional regulation and chromatin remodeling to protein degradation and cytoskeletal regulation. Specificity of function is determined in part by additional domains present in a given BTB protein, as well as by interaction partners.
  • Studies of BTB proteins in Drosophila and mammalian systems have revealed the importance of these proteins in multiple developmental contexts, as well as in cancer and neurological and musculoskeletal diseases.
  • BTB proteins play critical roles in transcriptional regulation and chromatin remodeling (Chaharbakhshi et al., Genesis 54:505-518 (2016)). [0009] The BTB domain mediates various functions of BCL6, such as homodimerization and interaction with co-repressor proteins (Ghetu et al., Mol. Cell 29:384-391 (2008); Ahmad et al., Mol. Cell 12:1551-1564 (2003)). Techniques that disrupt the protein-protein interaction between the BTB domain of BCL6 and its co-repressors may be useful to combat BCL6-related diseases.
  • a first aspect of the present disclosure is directed to a compound having a structure represented by formula (I): pharmaceutically acceptable salt or stereoisomer thereof, wherein: X 1 is N, CH, CCl, CF, or CCN; X 2 is N or CR 4 ; R4 is H, (C1-C4)alkyl, halo, OH, NH2, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, NO 2 , CN, NH(C 1 -C 4 )alkyl, or N(C 1 -C 4 alkyl) 2 ; R 1 is H, OH, or halo; R2 is H, OH, or halo; R3 is H, halo, or CN; Y is CH 2 ,
  • X 3 is CH or N;
  • R 5 is H, (C 1 -C 6 )alkyl, (C 1 -C 6 ) hydroxyalkyl, (C 1 -C 6 ) aminoalkyl, (C 3 -C 6 )carbocyclyl, 4- to 7- membered heterocyclyl, (C1-C6)alkyl-(C3-C7)carbocyclyl, or (C3-C7)carbocyclyl-4- to 7- membered heterocyclyl; wherein said alkyl, carbocyclyl, or heterocyclyl is further optionally substituted by one or more, identical or different R 13 groups, wherein R 13 is (C 1 -C 6 )alkyl, (C 1 - C6)alkoxy, halo, NH2, OH, (C1-C6)haloalkyl, NH(C1-C6)alkyl, or N((C1-C6)alkyl)2, (C3- C6)car
  • Another aspect of the present disclosure is directed to a pharmaceutical composition that includes a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.
  • a further aspect of the present disclosure is directed to a method of treating a disease or disorder that involves aberrant BCL6 activity that entails administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the disease or disorder is cancer.
  • the disease or disorder is an inflammatory disease.
  • the cancer is a lymphoid malignancy.
  • the lymphoid malignancy is peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia/lymphoma (ALL), cutaneous T-cell lymphoma, chronic myeloid leukemia, or B-cell non-Hodgkin’s lymphoma.
  • PTCL peripheral T-cell lymphoma
  • DLBCL diffuse large B-cell lymphoma
  • MCL mantle cell lymphoma
  • FL follicular lymphoma
  • CLL chronic lymphocytic leukemia
  • ALL acute lymphoblastic leukemia/lymphoma
  • cutaneous T-cell lymphoma chronic myeloid leukemia
  • B-cell non-Hodgkin B-cell non-Hodgkin
  • the term “about” means within 10% (e.g., within 5%, 2%, or 1%) of the particular value modified by the term “about.”
  • the transitional term “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. When used in the context of the number of heteroatoms in a heterocyclic structure, it means that the heterocyclic group that has that minimum number of heteroatoms. By contrast, the transitional phrase “consisting of” excludes any element, step, or ingredient not specified in the claim.
  • alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical. In some embodiments, the alkyl radical is a C1-C6 group.
  • the alkyl radical is a C 0 -C 6 , C 0 -C 5 , C 0 -C 3 , C 1 -C 6 , C 1 -C 5 , C 1 -C 4 or C 1 -C 3 group (wherein C 0 alkyl refers to a bond).
  • alkyl groups include methyl, ethyl, 1- propyl, 2-propyl, i-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, n- pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1- butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3- methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.
  • an alkyl group is a C 1 -C 3 alkyl group. In some embodiments, an alkyl group is a C 1 - C 2 alkyl group. In some embodiments, an alkyl group is a methyl group.
  • alkylene refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to six carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain may be attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • an alkylene group contains one to four carbon atoms (C 1 -C 4 alkylene). In other embodiments, an alkylene contains one to three carbon atoms (C1-C3 alkylene). In other embodiments, an alkylene group contains one to two carbon atoms (C1-C2 alkylene). In other embodiments, an alkylene group contains one carbon atom (C1 alkylene). [0021] As used herein, the term "alkenyl" refers to a linear or branched-chain monovalent hydrocarbon radical with at least one carbon-carbon double bond.
  • alkenyl includes radicals having "cis” and “trans” orientations, or alternatively, "E” and “Z” orientations.
  • the alkenyl radical is a C 2 -C 15 group.
  • the alkenyl radical is a C2-C12, C2-C10, C2-C8, C2-C6 or C2-C3 group.
  • alkynyl refers to a linear or branched monovalent hydrocarbon radical with at least one carbon-carbon triple bond.
  • the alkynyl radical is a C 2 -C 15 group. In some embodiments, and to the extent not disclosed otherwise for any one or more groups of the compounds of formula (I), the alkynyl radical is C2-C12, C2-C10, C2-C8, C2-C6 or C2- C3. Examples include ethynyl prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl and but-3-ynyl. [0023]
  • alkoxyl or “alkoxy” as used herein refer to an alkyl group, as defined above, having an oxygen radical attached thereto, and which is the point of attachment.
  • the alkoxyl group is methoxy, ethoxy, propyloxy, or tert-butoxy.
  • An “ether” is two hydrocarbyl groups covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of -O- alkyl, -O-alkenyl, and -O-alkynyl.
  • halogen or “halo” or “halide” refers to fluorine, chlorine, bromine, or iodine.
  • cyclic group broadly refers to any group that used alone or as part of a larger moiety, contains a saturated, partially saturated or aromatic ring system e.g., carbocyclic (cycloalkyl, cycloalkenyl), heterocyclic (heterocycloalkyl, heterocycloalkenyl), aryl and heteroaryl groups. Cyclic groups may have one or more (e.g., fused) ring systems. Therefore, for example, a cyclic group can contain one or more carbocyclic, heterocyclic, aryl or heteroaryl groups.
  • carbocyclic refers to a group that used alone or as part of a larger moiety, contains a saturated, partially unsaturated, or aromatic ring system having 3 to 12 carbon atoms, that is alone or part of a larger moiety (e.g., an alkylcarbocyclic group).
  • carbocyclyl includes mono-, bi-, tri-, fused, bridged, and spiro- ring systems, and combinations thereof.
  • carbocyclyl includes 3 to 10 carbon atoms (C3-C10).
  • carbocyclyl includes 3 to 6 carbon atoms (C3-C6).
  • carbocyclyl includes 5 to 6 carbon atoms (C5-C6). In some embodiments, carbocyclyl, as a bicycle, includes C 6 -C 10 . In another embodiment, carbocyclyl, as a spiro system, includes C 5 -C 11 .
  • monocyclic carbocyclyls include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and phenyl; bicyclic carbocyclyls having 7 to 11 ring atoms include [4,3], [4,4], [4,5], [5,5], [5,6] or [6,6] ring systems, such as for example bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, naphthalene, and bicyclo[3.2.2]n
  • spiro carbocyclyls include spiro[2.2]pentane, spiro[2.3]hexane, spiro[2.4]heptane, spiro[2.5]octane and spiro[4.5]decane.
  • carbocyclyl includes aryl ring systems as defined herein.
  • carbocycyl also includes cycloalkyl rings (e.g., saturated or partially unsaturated mono-, bi-, or spiro-carbocycles).
  • carbocyclic group also includes a carbocyclic ring fused to one or more (e.g., 1, 2 or 3) different cyclic groups (e.g., aryl or heterocyclic rings), where the radical or point of attachment is on the carbocyclic ring.
  • carbocyclic also embraces carbocyclylalkyl groups which as used herein refer to a group of the formula --R c -carbocyclyl where R c is an alkylene chain.
  • carbocyclic also embraces carbocyclylalkoxy groups which as used herein refer to a group bonded through an oxygen atom of the formula --O--R c -carbocyclyl where R c is an alkylene chain.
  • aryl used alone or as part of a larger moiety (e.g., "aralkyl", wherein the terminal carbon atom on the alkyl group is the point of attachment, e.g., a benzyl group),"aralkoxy” wherein the oxygen atom is the point of attachment, or "aroxyalkyl” wherein the point of attachment is on the aryl group) refers to a group that includes monocyclic, bicyclic or tricyclic, carbon ring system, that includes fused rings, wherein at least one ring in the system is aromatic.
  • the aralkoxy group is a benzoxy group.
  • aryl may be used interchangeably with the term "aryl ring".
  • aryl includes groups having 6-12 carbon atoms.
  • aryl includes groups having 6-10 carbon atoms.
  • Examples of aryl groups include phenyl, naphthyl, biphenyl, 1,2,3,4-tetrahydronaphthalenyl, and the like, which may be substituted or independently substituted by one or more substituents described herein.
  • a particular aryl is phenyl.
  • an aryl group includes an aryl ring fused to one or more (e.g., 1, 2 or 3) different cyclic groups (e.g., carbocyclic rings or heterocyclic rings), where the radical or point of attachment is on the aryl ring.
  • aryl embraces aralkyl groups (e.g., benzyl) which as disclosed above refer to a group of the formula --R c -aryl where R c is an alkylene chain such as methylene or ethylene.
  • the aralkyl group is an optionally substituted benzyl group.
  • aryl also embraces aralkoxy groups which as used herein refer to a group bonded through an oxygen atom of the formula --O—R c --aryl where R c is an alkylene chain such as methylene or ethylene.
  • heterocyclyl refers to a "carbocyclyl” that used alone or as part of a larger moiety, contains a saturated, partially unsaturated or aromatic ring system, wherein one or more (e.g., 1, 2, 3, 4, or 5) carbon atoms have been replaced with a heteroatom or heteroatom- containing group (e.g., O, N, N(O), S, S(O), or S(O)2).
  • heterocyclyl includes mono-, bi- , tri-, fused, bridged, and spiro-ring systems, and combinations thereof.
  • a heterocyclyl refers to a 3- to 12-membered heterocyclyl ring system.
  • a heterocyclyl refers to a saturated ring system, such as a 3- to 12-membered saturated heterocyclyl ring system.
  • a heterocyclyl refers to a heteroaryl ring system, such as a 5- to 12-membered heteroaryl ring system.
  • heterocyclyl also includes C 2 -C 8 heterocycloalkyl, which is a saturated or partially unsaturated mono-, bi-, or spiro-ring system containing 2-8 carbons and one or more (e.g., 1, 2, or 3) heteroatoms.
  • a heterocyclyl group includes 3-12 ring atoms and includes monocycles, bicycles, tricycles and spiro ring systems, wherein the ring atoms are carbon, and one to 5 ring atoms is a heteroatom such as nitrogen, sulfur or oxygen.
  • heterocyclyl includes 3- to 7-membered monocycles having one or more heteroatoms selected from O, N, and S.
  • heterocyclyl includes 4- to 6-membered monocycles having one or more heteroatoms selected from O, N, and S. In some embodiments, heterocyclyl includes 3-membered monocycles. In some embodiments, heterocyclyl includes 4-membered monocycles. In some embodiments, heterocyclyl includes 5- to 6-membered monocycles. In some embodiments, the heterocyclyl group includes 0 to 3 double bonds. In any of the foregoing embodiments, heterocyclyl includes 1, 2, 3 or 4 heteroatoms.
  • Any nitrogen or sulfur heteroatom may optionally be oxidized (e.g., NO, SO, SO2), and any nitrogen heteroatom may optionally be substituted (e.g., methyl, isopropyl) and/or quaternized (e.g., [NR4] + Cl-, [NR4] + OH-).
  • heterocyclyls include oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl, dihydro-1H-pyrrolyl, dihydrofuranyl, tetrahydropyranyl, dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, dihydropyranyl, tetrahydropyranyl, hexahydrothiopyranyl, hexahydropyrimidinyl, oxazinanyl, thiazinanyl, thioxanyl, homopiperazinyl, homopiperidinyl,
  • Examples of 5-membered heterocyclyls containing a sulfur or oxygen atom and one to three nitrogen atoms are thiazolyl (e.g., thiazol-2-yl), thiadiazolyl (e.g., 1,3,4- thiadiazol-5-yl and 1,2,4-thiadiazol-5-yl), oxazolyl (e.g., oxazol-2-yl), and oxadiazolyl (e.g., 1,3,4- oxadiazol-5-yl and 1,2,4-oxadiazol-5-yl).
  • thiazolyl e.g., thiazol-2-yl
  • thiadiazolyl e.g., 1,3,4- thiadiazol-5-yl and 1,2,4-thiadiazol-5-yl
  • oxazolyl e.g., oxazol-2-yl
  • oxadiazolyl e.g., 1,3,4- oxadia
  • Example of 5-membered heterocyclyls containing 2 to 4 nitrogen atoms include imidazolyl (e.g., imidazol-2-yl), triazolyl (e.g., 1,3,4-triazol-5-yl, 1,2,3- triazol-5-yl, and 1,2,4-triazol-5-yl), and tetrazolyl (e.g., 1H-tetrazol-5-yl).
  • Representative examples of benzo-fused 5-membered heterocyclyls include benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl.
  • Example of 6-membered heterocyclyls containing one to three nitrogen atoms and optionally a sulfur or oxygen atom are pyridyl (e.g., pyrid-2-yl, pyrid-3-yl, and pyrid- 4-yl), pyrimidyl (e.g., pyrimid-2-yl and pyrimid-4-yl), triazinyl (e.g., 1,3,4-triazin-2-yl and 1,3,5- triazin-4-yl), pyridazinyl (e.g., pyridazin-3-yl), and pyrazinyl.
  • pyridyl e.g., pyrid-2-yl, pyrid-3-yl, and pyrid- 4-yl
  • pyrimidyl e.g., pyrimid-2-yl and pyrimid-4-yl
  • triazinyl e.g.,
  • a heterocyclic group includes a heterocyclic ring fused to one or more (e.g., 1 or 2) different cyclic groups (e.g., carbocyclic rings or heterocyclic rings), where the radical or point of attachment is on the heterocyclic ring, and in some embodiments wherein the point of attachment is a heteroatom contained in the heterocyclic ring.
  • the term heterocyclic embraces N-heterocyclyl groups which as used herein refer to a heterocyclyl group containing at least one nitrogen atom and where the point of attachment of the heterocyclyl group to the rest of the molecule is through a nitrogen atom in the heterocyclyl group.
  • N-heterocyclyl groups include 1-morpholinyl, 1- piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, 1-pyrazolidinyl, 1-imidazolinyl and 1-imidazolidinyl.
  • heterocyclic also embraces C-heterocyclyl groups which as used herein refer to a heterocyclyl group containing at least one heteroatom and where the point of attachment of the heterocyclyl group to the rest of the molecule is through a carbon atom in the heterocyclyl group.
  • Representative examples of C-heterocyclyl radicals include 2- or 3-morpholinyl, 2- or 3- or 4- piperidinyl, 2-piperazinyl, and 2- or 3-pyrrolidinyl.
  • heterocyclic also embraces heterocyclylalkyl groups which as disclosed above refer to a group of the formula --R c - heterocyclyl where R c is an alkylene chain.
  • heterocyclic also embraces heterocyclylalkoxy groups which as used herein refer to a radical bonded through an oxygen atom of the formula --O--R c -heterocyclyl where R c is an alkylene chain.
  • heteroaryl used alone or as part of a larger moiety (e.g., “heteroarylalkyl” (also “heteroaralkyl”), or “heteroarylalkoxy” (also “heteroaralkoxy”)) refers to a monocyclic, bicyclic or tricyclic ring system having 5 to 12 ring atoms, wherein at least one ring is aromatic and contains at least one heteroatom.
  • heteroaryl includes 5- to 6- membered monocyclic aromatic groups where one or more ring atoms is O, N, or S.
  • heteroaryl groups include thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, imidazopyridyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, tetrazolo[1,5-b]pyridazinyl, purinyl, deazapurinyl, benzoxazolyl, benzofuryl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoimidazolyl, indolyl, 1,3-thiazol-2-yl, 1,3,4-triazol-5-
  • heteroaryl also includes groups in which a heteroaryl is fused to one or more cyclic (e.g., carbocyclyl, or heterocyclyl) rings, where the radical or point of attachment is on the heteroaryl ring.
  • cyclic e.g., carbocyclyl, or heterocyclyl
  • Nonlimiting examples include indolyl, indolizinyl, isoindolyl, benzothienyl, benzothiophenyl, methylenedioxyphenyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzodioxazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and pyrido[2,3-b]- 1,4-oxazin-3(4H)-one.
  • a heteroaryl group may be mono-, bi- or tri-cyclic.
  • a heteroaryl group includes a heteroaryl ring fused to one or more (e.g., 1 or 2) different cyclic groups (e.g., carbocyclic rings or heterocyclic rings), where the radical or point of attachment is on the heteroaryl ring, and in some embodiments wherein the point of attachment is a heteroatom contained in the heterocyclic ring.
  • the term heteroaryl embraces N-heteroaryl groups which as used herein refer to a heteroaryl group as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl group to the rest of the molecule is through a nitrogen atom in the heteroaryl group.
  • heteroaryl also embraces C-heteroaryl groups which as used herein refer to a heteroaryl group as defined above and where the point of attachment of the heteroaryl group to the rest of the molecule is through a carbon atom in the heteroaryl group.
  • heteroaryl also embraces heteroarylalkyl groups which as disclosed above refer to a group of the formula --R c -heteroaryl, wherein R c is an alkylene chain as defined above.
  • heteroaryl also embraces heteroaralkoxy (or heteroarylalkoxy) groups which as used herein refer to a group bonded through an oxygen atom of the formula --O--R c -heteroaryl, where R c is an alkylene group as defined above.
  • any of the groups described herein may be substituted or unsubstituted.
  • substituents may include alkyl (e.g., C 1 -C 6 , C 1 -C 5 , C 1 -C 4 , C 1 -C 3 , C 1 -C 2 , C 1 ), substituted alkyl (e.g., substituted C 1 -C 6 , C 1 -C 5 , C 1 -C 4 , C 1 -C 3 , C 1 -C 2 , C 1 ), alkoxy (e.g., C 1 -C 6 , C 1 - C5, C1-C4, C1-C3, C1-C2, C1), substituted alkoxy (e.g., substituted C1-C6, C1-C5, C1-C4, C1-C3,
  • Z is O. In some embodiments, Z is CH 2 . [0038] In some embodiments, Y is CH2. In some embodiments, Y is O. In some embodiments, Y is NH. [0039] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. [0040] In some embodiments, R 1 and R 2 are each H. In some embodiments, R 1 and R 2 are each halo. In some embodiments, R 1 and R 2 are each F. [0041] In some embodiments, R3 is halo. In some embodiments, R3 is Cl. [0042] In some embodiments, X1 is N.
  • X 2 is CH.
  • Z is O and Y is CH2. In some embodiments, Z is O and Y is O. In some embodiments, Z is O and Y is NH. In some embodiments, Z is CH2 and Y is CH2. In some embodiments, Z is CH 2 and Y is O. In some embodiments, Z is CH 2 and Y is NH. [0045] In some embodiments, Z is O, Y is CH 2 , and n is 1. In some embodiments, Z is O, Y is O, and n is 1. In some embodiments, Z is O, Y is NH, and n is 1. In some embodiments, Z is CH2, Y is CH2, and n is 1.
  • Z is CH2, Y is O, and n is 1. In some embodiments, Z is CH2, Y is NH, and n is 1. [0046] In some embodiments, Z is O, Y is CH 2 , n is 1, and R 1 and R 2 are each H or F. In some embodiments, Z is O, Y is O, n is 1, and R1 and R2 are each H or F. In some embodiments, Z is O, Y is NH, n is 1, and R1 and R2 are each H or F. In some embodiments, Z is CH2, Y is CH2, n is 1, and R 1 and R 2 are each H or F.
  • Z is CH 2 , Y is O, n is 1, and R 1 and R 2 are each H or F. In some embodiments, Z is CH 2 , Y is NH, n is 1, and R 1 and R 2 are each H or F. [0047] In some embodiments, Z is O, Y is CH2, n is 1, R1 and R2 are each H or F, and R3 is Cl. In some embodiments, Z is O, Y is O, n is 1, R 1 and R 2 are each H or F, and R 3 is Cl. In some embodiments, Z is O, Y is NH, n is 1, R 1 and R 2 are each H or F, and R 3 is Cl.
  • Z is CH2, Y is CH2, n is 1, R1 and R2 are each H or F, and R3 is Cl. In some embodiments, Z is CH2, Y is O, n is 1, R1 and R2 are each H or F, and R3 is Cl. In some embodiments, Z is CH 2 , Y is NH, n is 1, R 1 and R 2 are each H or F, and R 3 is Cl. [0048] In some embodiments, Z is O, Y is CH2, n is 1, R1 and R2 are each H or F, R3 is Cl, and X1 and X2 are independently N or CH.
  • Z is O, Y is O, n is 1, R1 and R2 are each H or F, R 3 is Cl, and X 1 and X 2 are independently N or CH.
  • Z is O, Y is NH, n is 1, R 1 and R 2 are each H or F, R 3 is Cl, and X 1 and X 2 are independently N or CH.
  • Z is CH2, Y is CH2, n is 1, R1 and R2 are each H or F, R3 is Cl, and X1 and X2 are independently N or CH.
  • Z is CH 2 , Y is O, n is 1, R 1 and R 2 are each H or F, R 3 is Cl, and X 1 and X 2 are independently N or CH.
  • Z is CH 2 , Y is NH, n is 1, R1 and R2 are each H or F, R3 is Cl, and X1 and X2 are independently N or CH.
  • the compounds of the disclosure are represented any of formulas (Ia-If):
  • A is and the compound of formula (I) has the structure of formula I-1, or a pharmaceutically acceptable salt or stereoisomer thereof.
  • R5 is optionally substituted (C1-C6)alkyl. In some embodiments of formula I-1, R 5 is methyl.
  • X3 is CH.
  • R6 is –L1CR14R15R16. In some embodiments of formula I-1, L 1 is -O-(C 1 -C 4 )alkylene.
  • L 1 is -O-(C 1 )alkylene.
  • R16 is methyl, OH, NH2, or NHMe. In some embodiments of formula I-1, R 16 is NHMe.
  • R 5 is (C 1 -C 6 )alkyl
  • X 3 is CH
  • R16 is methyl, OH, NH2, or NHMe.
  • the compound of formula I-1 is of formula I-1a, R R (I-1a), or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula I-1a is of formula I-1a1 or I-1ab, pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula (I) has the structure of formula (I-2), or a pharmaceutically acceptable salt or stereoisomer thereof.
  • R5 is optionally substituted (C1-C6)alkyl. In some embodiments of formula I-2, R5 is methyl.
  • R 7 is —(CH 2 ) 1-3 W 1 W 2 . In some embodiments of formula I-2, R 7 is –(CH 2 ) 2 W 1 W 2 . In some embodiments of formula I-2, W 1 is CR 19 R 19’ . In some embodiments of formula I-2, R19 and R19’ are both methyl.
  • W 2 is CN, OH, or NH 2 . In some embodiments of formula I-2, W 2 is OH. In some embodiments of formula I-2, R 7 is H. In some embodiments of formula I-2, R 7 is methyl. [0061] In some embodiments of formula I-2, R7 is –(CH2)1-2W1W2. In some embodiments of formula I-2, W 1 is CR 19 R 19’ . In some embodiments of formula I-2, R 19 and R 19’ are independently H, OH, or methyl. In some embodiments of formula I-2, W 2 is CR 20 R 21 R 22 . In some embodiments of formula I-2, R20 and R21 are both H and R22 is OH.
  • R20 and R21 are both methyl and R22 is OH. In some embodiments of formula I-2, R20 and R21 are both H and R22 is S(O)(NH)-(C1-C2)alkyl. In some embodiments of formula I-2, R20 and R21 together with the carbon atom to which they are attached form 4- to 6-membered heterocyclyl, optionally substituted by one or more substituents selected from (C1-C2)alkyl, halo, (C1-C2)haloalkyl, (C1- C2)haloalkoxy, (C1-C2)alkoxy, (C1-C2)alkylamino, NH2, CN, and OH, and R22 is OH.
  • R 5 is (C 1 -C 6 )alkyl and R 7 is –(CH 2 ) 1-3 W 1 W 2 .
  • R 5 is methyl and R 7 is –(CH 2 ) 2 W 1 W 2 , wherein W 1 is CR 19 R 19’ , wherein R19 and R19’ are both methyl, and W2 is CN, OH, or NH2.
  • R 5 is (C 1 -C 6 )alkyl and R 7 is H. In some embodiments of formula I-2, R 5 is methyl and R 7 is H.
  • R5 is (C1-C6)alkyl and R7 is methyl. In some embodiments of formula I-2, R5 is methyl and R7 is methyl. [0065] In some embodiments of formula I-2, R 5 is (C 1 -C 6 )alkyl and R 7 is –(CH 2 ) 1-2 W 1 W 2 , wherein W1 is CR19R19’ and W2 is CR20R21R22. In some embodiments of formula I-2, R19 and R19’ are independently H, OH, or methyl. In some embodiments of formula I-2, R20 and R21 are both H and R 22 is OH.
  • R 20 and R 21 are both methyl and R 22 is OH. In some embodiments of formula I-2, R 20 and R 21 are both H and R 22 is S(O)(NH)-(C 1 -C 2 )alkyl.
  • R20 and R21 together with the carbon atom to which they are attached form 4- to 6-membered heterocyclyl, optionally substituted by one or more substituents selected from (C 1 -C 2 )alkyl, halo, (C 1 -C 2 )haloalkyl, (C 1 -C 2 )haloalkoxy, (C 1 -C 2 )alkoxy, (C 1 - C2)alkylamino, NH2, CN, and OH, and R22 is OH.
  • the compound of formula I-2 is of formula I-2a
  • the compound of formula I-2a is of formula I-2a1 or I-2a2, a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula I-2 is of formula I-2b, pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula I-2b is of formula I-2b1 or I-2b2, a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula I-2 is of formula I-2c
  • the compound of formula I-2c is of formula I-2c1 or I-2c2, or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula (I) has the structure of formula pharmaceutically acceptable salt or stereoisomer thereof.
  • R5 is optionally substituted (C1-C6)alkyl.
  • R5 is methyl.
  • R 8 is (C 3 -C 6 )cycloalkyl and R 8 ’ is H.
  • R 8 is cyclopropyl and R 8 ’ is H.
  • A’ is a 7-membered heterocyclyl, wherein the heterocyclyl contains 2 heteroatoms selected from N and O, and which in addition to R 8 and R 8 ’, is optionally further substituted by one more substituents independently selected from oxo, (C 1 - C2)alkyl, cyclopropyl, spiro-cyclopropyl, halo, (C1-C2)haloalkyl, (C1-C2)alkoxy, NH2, CN, and OH.
  • R5 is (C1-C6)alkyl
  • R8 is (C3-C6)cycloalkyl
  • R8’ is H
  • A’ is a 7-membered heterocyclyl, wherein the heterocyclyl contains 2 heteroatoms selected from N and O, and which in addition to R 8 and R 8 ’, is optionally further substituted by one more substituents independently selected from oxo, (C1-C2)alkyl, cyclopropyl, spiro-cyclopropyl, halo, (C1-C2)haloalkyl, (C1-C2)alkoxy, NH2, CN, and OH.
  • the compound of formula I-3 is of formula I-3a, pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula I-3a is of formula I-3a1 or I-3a2, (I-3a2), or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula (I) has the structure of formula pharmaceutically acceptable salt or stereoisomer thereof.
  • R5 is optionally substituted (C1-C6)alkyl. In some embodiments of formula I-4, R 5 is methyl.
  • X4 is CH. In some embodiments of formula I-4, X4 is NH.
  • A is and the compound of formula (I) has the structure of formula I pharmaceutically acceptable salt or stereoisomer thereof.
  • R 5 is 4-membered heterocyclyl or 4-membered heterocyclyl(C2)alkyl; wherein said alkyl, carbocyclyl, or heterocyclyl is further optionally substituted by one or more, identical or different R 13 groups.
  • R2 is 4-membered heterocyclyl or 4-membered heterocyclyl(C2)alkyl, wherein the heterocyclyl contains 1 heteroatom selected from N and O.
  • R 2 is (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-OH, (C 1 -C 6 )alkyl- NH(C1-C6)alkyl, or (C1-C6)alkyl-N((C1-C6)alkyl)2.
  • R6 is –L1CR14R15R16.
  • L 1 is -O-(C 1 -C 4 )alkylene.
  • L 1 is -O-(C 1 )alkylene.
  • R16 is methyl, OH, NH2, or NHMe.
  • R 16 is NHMe.
  • the compound of formula (I) has the structure of formula I-6, (I-6), or a pharmaceutically acceptable salt or stereoisomer thereof.
  • R 5 is optionally substituted (C 1 -C 6 )alkyl.
  • R5 is methyl.
  • m is 0.
  • m is 1.
  • X 5 is absent.
  • o is 0.
  • o is 1.
  • R10 and R11 are each H and R10’ and R11’, together with the carbon atoms to which they are attached, form cyclobutyl.
  • R 12 is OH.
  • R5 is (C1-C6)alkyl, m is 1, X5 is absent, o is 1, R10 and R11 are each H and R10’ and R11’, together with the carbon atoms to which they are attached, form cyclobutyl, and R 12 is OH.
  • R 5 is (C 1 -C 6 )alkyl, m is 0, X 5 is absent, o is 0, and R12 is H.
  • the compound of formula I-6 is of formula I-6a, pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound of formula I-6a is of formula I-6a1 or I-6a2, a pharmaceutically acceptable salt or stereoisomer thereof. 35 [0099] In some embodiments, the compound of formula I-6 is of formula I-6b, R R (I-6b), or a pharmaceutically acceptable salt or stereoisomer thereof. [00100] In some embodiments, the compound of formula I-6b is of formula I-6b1 or I-6b2, a pharmaceutically acceptable salt or stereoisomer thereof. [00101] In some embodiments of formulas I-1a to I-6b, Z is O. In some embodiments of formulas I-1a to I-6b, Z is CH2.
  • Y is CH 2 . In some embodiments of formulas I-1a to I-6b, Y is O. In some embodiments, Y is NH. [00103] In some embodiments of formulas I-1a to I-6b, n is 0. In some embodiments of formulas I-1a to I-6b, n is 1. In some embodiments of formulas I-1a to I-6b, n is 2. [00104] In some embodiments of formulas I-1a to I-6b, R 1 and R 2 are each H. In some embodiments of formulas I-1a to I-6b, R1 and R2 are each halo.
  • R1 and R2 are each F.
  • R 3 is halo.
  • R3 is Cl.
  • R3 is F.
  • X1 is N.
  • X 2 is CH.
  • Z is O and Y is CH 2 .
  • Z is O and Y is O. In some embodiments of formulas I-1a to I-6b, Z is O and Y is NH. In some embodiments of formulas I-1a to I-6b, Z is CH 2 and Y is CH2. In some embodiments of formulas I-1a to I-6b, Z is CH2 and Y is O. In some embodiments of formulas I-1a to I-6b, Z is CH2 and Y is NH. [00109] In some embodiments of formulas I-1a to I-6b, Z is O, Y is CH 2 , and n is 1. In some embodiments of formulas I-1a to I-6b, Z is O, Y is O, and n is 1.
  • Z is O, Y is NH, and n is 1. In some embodiments of formulas I-1a to I-6b, Z is CH2, Y is CH 2 , and n is 1. In some embodiments of formulas I-1a to I-6b, Z is CH 2 , Y is O, and n is 1. In some embodiments of formulas I-1a to I-6b, Z is CH 2 , Y is NH, and n is 1. [00110] In some embodiments of formulas I-1a to I-6b, Z is O, Y is CH2, n is 1, and R1 and R2 are each H or F.
  • Z is O, Y is O, n is 1, and R 1 and R 2 are each H or F.
  • Z is O, Y is NH, n is 1, and R 1 and R2 are each H or F.
  • Z is CH2, Y is CH2, n is 1, and R1 and R2 are each H or F.
  • Z is CH2, Y is O, n is 1, and R 1 and R 2 are each H or F.
  • Z is CH 2 , Y is NH, n is 1, and R1 and R2 are each H or F. [00111] In some embodiments of formulas I-1a to I-6b, Z is O, Y is CH2, n is 1, R1 and R2 are each H or F, and R 3 is Cl or F. In some embodiments of formulas I-1a to I-6b, Z is O, Y is O, n is 1, R 1 and R 2 are each H or F, and R 3 is Cl or F. In some embodiments of formulas I-1a to I-6b, Z is O, Y is NH, n is 1, R1 and R2 are each H or F, and R3 is Cl or F.
  • Z is CH 2 , Y is CH 2 , n is 1, R 1 and R 2 are each H or F, and R 3 is Cl or F.
  • Z is CH 2 , Y is O, n is 1, R 1 and R 2 are each H or F, and R3 is Cl or F.
  • Z is CH2, Y is NH, n is 1, R1 and R 2 are each H or F, and R 3 is Cl or F.
  • Z is O, Y is CH 2 , n is 1, R 1 and R 2 are each H or F, R3 is Cl or F, and X1 and X2 are independently N or CH.
  • Z is O, Y is O, n is 1, R1 and R2 are each H or F, R3 is Cl or F, and X1 and X 2 are independently N or CH.
  • Z is O, Y is NH, n is 1, R1 and R2 are each H or F, R3 is Cl or F, and X1 and X2 are independently N or CH.
  • Z is CH2, Y is CH2, n is 1, R1 and R2 are each H or F, R3 is Cl or F, and X 1 and X 2 are independently N or CH.
  • Z is CH 2 , Y is O, n is 1, R 1 and R 2 are each H or F, R 3 is Cl or F, and X 1 and X 2 are independently
  • Compounds of the present disclosure may be in the form of a free acid or free base, or a pharmaceutically acceptable salt.
  • a pharmaceutically acceptable salt of the compounds of this disclosure can be formed, for example, by reaction of an appropriate free base of a compound of the invention and an appropriate pharmaceutically acceptable acid in a suitable solvent under standard conditions well known in the art. See, for example, Gould, P. L., "Salt selection for basic drugs," International Journal of Pharmaceutics, 33:201-217 (1986); Bastin, R. J., et al., “Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities," Organic Process Research and Development, 4:427-435 (2000); and Berge, S.
  • Compounds of the present disclosure may have at least one chiral center and thus may be in the form of a stereoisomer, which as used herein, embraces all isomers of individual compounds that differ only in the orientation of their atoms in space.
  • stereoisomer includes mirror image isomers (enantiomers which include the (R-) or (S-) configurations of the compounds), mixtures of mirror image isomers (physical mixtures of the enantiomers, and racemates or racemic mixtures) of compounds, geometric (cis/trans or E/Z, R/S) isomers of compounds and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereoisomers).
  • the chiral centers of the compounds may undergo epimerization in vivo; thus, for these compounds, administration of the compound in its (R-) form is considered equivalent to administration of the compound in its (S-) form.
  • the compounds of the present disclosure may be made and used in the form of individual isomers and substantially free of other isomers, or in the form of a mixture of various isomers, e.g., racemic mixtures of stereoisomers.
  • the compound of formula (I) is an isotopic derivative in that it has at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched.
  • the compound includes deuterium or multiple deuterium atoms.
  • hydrogen i.e. H, refers to all isotopes of hydrogen, including protium ( 1 H) and deuterium ( 2 H).
  • the term “compound” embraces isotopic derivatives.
  • Compounds of formula (I) may also be in the form of N-oxides, crystalline forms (also known as polymorphs), co-crystals, active metabolites of the compounds having the same type of activity, prodrugs, tautomers, and unsolvated as well as solvated (e.g., hydrated) forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, of the compounds.
  • the term “compound” embraces all these forms.
  • the compounds of formula (I) may be prepared by crystallization under different conditions and may exist as one or a combination of polymorphs of the compound.
  • the pharmaceutical composition comprises a co-crystal of a compound of formula (I).
  • co-crystal refers to a stoichiometric multi-component system comprising a compound of formula (I) and a co-crystal former wherein the compound of formula (I) and the co-crystal former are connected by non-covalent interactions.
  • co-crystal former refers to compounds which can form intermolecular interactions with a compound of formula (I) and co-crystallize with it.
  • co-crystal formers include benzoic acid, succinic acid, fumaric acid, glutaric acid, trans-cinnamic acid, 2,5-dihydroxybenzoic acid, glycolic acid, trans-2-hexanoic acid, 2-hydroxycaproic acid, lactic acid, sorbic acid, tartaric acid, ferulic acid, suberic acid, picolinic acid, salicylic acid, maleic acid, saccharin, 4,4’-bipyridine p-aminosalicylic acid, nicotinamide, urea, isonicotinamide, methyl-4-hydroxybenzoate, adipic acid, terephthalic acid, resorcinol, pyrogallol, phloroglucinol, hydroxyquinol, isoniazid, theophylline, adenine, theobromine, phenacetin, phenazone, etofylline, and phenobarbital.
  • the present disclosure is directed to a method for making a compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compounds of formula (I) or pharmaceutically acceptable salts or stereoisomers thereof may be prepared by any process known to be applicable to the preparation of chemically related compounds.
  • the compounds of formula (I) will be better understood in connection with the synthetic schemes that described in various working examples that illustrate non-limiting methods by which the compounds of formula (I) may be prepared.
  • Pharmaceutical Compositions [00121] Another aspect of the present disclosure is directed to a pharmaceutical composition that includes a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.
  • Suitable carriers refers to a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present disclosure to mammals.
  • Suitable carriers may include, for example, liquids (both aqueous and non-aqueous alike, and combinations thereof), solids, encapsulating materials, gases, and combinations thereof (e.g., semi-solids), and gases, that function to carry or transport the compound from one organ, or portion of the body, to another organ, or portion of the body.
  • a carrier is “acceptable” in the sense of being physiologically inert to and compatible with the other ingredients of the formulation and not injurious to the subject or patient.
  • the composition may also include one or more pharmaceutically acceptable excipients.
  • compounds of formula (I) and their pharmaceutically acceptable salts and stereoisomers may be formulated into a given type of composition in accordance with conventional pharmaceutical practice such as conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping and compression processes (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
  • the type of formulation depends on the mode of administration which may include enteral (e.g., oral, buccal, sublingual and rectal), parenteral (e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), and intrasternal injection, or infusion techniques, intra-ocular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, interdermal, intravaginal, intraperitoneal, mucosal, nasal, intratracheal instillation, bronchial instillation, and inhalation) and topical (e.g., transdermal).
  • enteral e.g., oral, buccal, sublingual and rectal
  • parenteral e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), and intrasternal injection
  • intra-ocular, intra-arterial, intramedullary intrathecal, intraventricular, transdermal, interderma
  • the most appropriate route of administration will depend upon a variety of factors including, for example, the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
  • parenteral (e.g., intravenous) administration may also be advantageous in that the compound may be administered relatively quickly such as in the case of a single-dose treatment and/or an acute condition.
  • the compounds of formula (I) are formulated for oral or intravenous administration (e.g., systemic intravenous injection).
  • compounds of formula (I) may be formulated into solid compositions (e.g., powders, tablets, dispersible granules, capsules, cachets, and suppositories), liquid compositions (e.g., solutions in which the compound is dissolved, suspensions in which solid particles of the compound are dispersed, emulsions, and solutions containing liposomes, micelles, or nanoparticles, syrups and elixirs); semi-solid compositions (e.g., gels, suspensions and creams); and gases (e.g., propellants for aerosol compositions).
  • solid compositions e.g., powders, tablets, dispersible granules, capsules, cachets, and suppositories
  • liquid compositions e.g., solutions in which the compound is dissolved, suspensions in which solid particles of the compound are dispersed, emulsions, and solutions containing liposomes, micelles, or nanoparticles, syrups and e
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with a carrier such as sodium citrate or dicalcium phosphate and an additional carrier or excipient such as a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as crosslinked polymers (e.g., crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose (croscarmellose sodium), sodium starch glycolate, agar-agar, calcium carbonate, potato or tapi
  • a carrier such as
  • the dosage form may also include buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings. They may further contain an opacifying agent.
  • compounds of formula (I) may be formulated in a hard or soft gelatin capsule.
  • Liquid dosage forms for oral administration include solutions, suspensions, emulsions, micro-emulsions, syrups and elixirs.
  • the liquid dosage forms may contain an aqueous or non-aqueous carrier (depending upon the solubility of the compounds) commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • an aqueous or non-aqueous carrier depending upon the solubility of the compounds commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol,
  • Oral compositions may also include an excipients such as wetting agents, suspending agents, coloring, sweetening, flavoring, and perfuming agents.
  • injectable preparations for parenteral administration may include sterile aqueous solutions or oleaginous suspensions. They may be formulated according to standard techniques using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. The effect of the compound may be prolonged by slowing its absorption, which may be accomplished by the use of a liquid suspension or crystalline or amorphous material with poor water solubility.
  • Prolonged absorption of the compound from a parenterally administered formulation may also be accomplished by suspending the compound in an oily vehicle.
  • compounds of formula (I) may be administered in a local rather than systemic manner, for example, via injection of the conjugate directly into an organ, often in a depot preparation or sustained release formulation.
  • long-acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • injectable depot forms are made by forming microencapsule matrices of the compound in a biodegradable polymer, e.g., polylactide-polyglycolides, poly(orthoesters) and poly(anhydrides).
  • the rate of release of the compound may be controlled by varying the ratio of compound to polymer and the nature of the particular polymer employed. Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues. Furthermore, in other embodiments, the compound is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. [00130] The compositions may be formulated for buccal or sublingual administration, examples of which include tablets, lozenges and gels. [00131] The compounds of formula (I) may be formulated for administration by inhalation.
  • compositions may be delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit of a pressurized aerosol may be determined by providing a valve to deliver a metered amount.
  • capsules and cartridges including gelatin may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • a powder mix of the compound may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • Compounds of formula (I) may be formulated for topical administration which as used herein, refers to administration intradermally of the formulation to the epidermis. These types of compositions are typically in the form of ointments, pastes, creams, lotions, gels, solutions and sprays.
  • Representative examples of carriers useful in formulating compounds for topical application include solvents (e.g., alcohols, poly alcohols, water), creams, lotions, ointments, oils, plasters, liposomes, powders, emulsions, microemulsions, and buffered solutions (e.g., hypotonic or buffered saline).
  • Creams for example, may be formulated using saturated or unsaturated fatty acids such as stearic acid, palmitic acid, oleic acid, palmito-oleic acid, cetyl, or oleyl alcohols. Creams may also contain a non-ionic surfactant such as polyoxy-40-stearate.
  • the topical formulations may also include an excipient, an example of which is a penetration enhancing agent.
  • an excipient an example of which is a penetration enhancing agent.
  • These agents are capable of transporting a pharmacologically active compound through the stratum corneum and into the epidermis or dermis, preferably, with little or no systemic absorption.
  • a wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. S for example, Percutaneous Penetration Enhancers, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, Fla.
  • penetration enhancing agents include triglycerides (e.g., soybean oil), aloe compositions (e.g., aloe-vera gel), ethyl alcohol, isopropyl alcohol, octolyphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters (e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate), and N-methylpyrrolidone.
  • aloe compositions e.g., aloe-vera gel
  • ethyl alcohol isopropyl alcohol
  • octolyphenylpolyethylene glycol oleic acid
  • polyethylene glycol 400 propylene glycol
  • N-decylmethylsulfoxide e.g., isopropyl myristate, methyl laur
  • compositions that may be included in topical as well as in other types of formulations (to the extent they are compatible), include preservatives, antioxidants, moisturizers, emollients, buffering agents, solubilizing agents, skin protectants, and surfactants.
  • Suitable preservatives include alcohols, quaternary amines, organic acids, parabens, and phenols.
  • Suitable antioxidants include ascorbic acid and its esters, sodium bisulfite, butylated hydroxytoluene, butylated hydroxyanisole, tocopherols, and chelating agents like EDTA and citric acid.
  • Suitable moisturizers include glycerin, sorbitol, polyethylene glycols, urea, and propylene glycol.
  • Suitable buffering agents include citric, hydrochloric, and lactic acid buffers.
  • Suitable solubilizing agents include quaternary ammonium chlorides, cyclodextrins, benzyl benzoate, lecithin, and polysorbates.
  • Suitable skin protectants include vitamin E oil, allatoin, dimethicone, glycerin, petrolatum, and zinc oxide.
  • Transdermal formulations typically employ transdermal delivery devices and transdermal delivery patches wherein the compound is formulated in lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. Patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Transdermal delivery of the compounds may be accomplished by means of an iontophoretic patch. Transdermal patches may provide controlled delivery of the compounds wherein the rate of absorption is slowed by using rate-controlling membranes or by trapping the compound within a polymer matrix or gel.
  • Absorption enhancers may be used to increase absorption, examples of which include absorbable pharmaceutically acceptable solvents that assist passage through the skin.
  • Ophthalmic formulations include eye drops.
  • Formulations for rectal administration include enemas, rectal gels, rectal foams, rectal aerosols, and retention enemas, which may contain conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like.
  • compositions for rectal or vaginal administration may also be formulated as suppositories which can be prepared by mixing the compound with suitable non-irritating carriers and excipients such as cocoa butter, mixtures of fatty acid glycerides, polyethylene glycol, suppository waxes, and combinations thereof, all of which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the compound.
  • suitable non-irritating carriers and excipients such as cocoa butter, mixtures of fatty acid glycerides, polyethylene glycol, suppository waxes, and combinations thereof, all of which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the compound.
  • terapéuticaally effective amount refers to an amount of a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof that is effective in producing the desired therapeutic response in a particular patient suffering from a disease or disorder mediated by aberrant BCL6 activity.
  • terapéuticaally effective amount thus includes the amount of the compound or a pharmaceutically acceptable salt or a stereoisomer thereof, that when administered, induces a positive modification in the disease or disorder to be treated, or is sufficient to prevent development or progression of the disease or disorder, or alleviate to some extent, one or more of the symptoms of the disease or disorder being treated in a subject, or which simply kills or inhibits the growth of diseased (e.g., cancer) cells, or reduces the amounts of BCL6 in diseased cells.
  • the total daily dosage of the compounds and usage thereof may be decided in accordance with standard medical practice, e.g., by the attending physician using sound medical judgment.
  • the specific therapeutically effective dose for any particular subject may depend upon a variety of factors including the disease or disorder being treated and the severity thereof (e.g., its present status); the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the compound; and like factors well known in the medical arts (see, for example, Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 10th Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173 (2001)).
  • the present disclosure is directed to treating diseases or disorders that involve (e.g., characterized or mediated by) aberrant (e.g., elevated levels of BCL6 or otherwise functionally abnormal e.g., deregulated BCL6 levels) BCL6 activity relative to a non-pathological state.
  • diseases and disorders include cancers and inflammatory diseases and disorders.
  • the methods entail administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof.
  • subject or “patient” as used herein includes all members of the animal kingdom prone to or suffering from the cancer.
  • the subject is a mammal, e.g., a human or a non-human mammal.
  • the methods are also applicable to companion animals such as dogs and cats.
  • a subject “in need of” treatment according to the present disclosure may be “suffering from or suspected of suffering from” a specific cancer may have been positively diagnosed or otherwise presents with a sufficient number of risk factors or a sufficient number or combination of signs or symptoms such that a medical professional could diagnose or suspect that the subject is suffering from the cancer.
  • subjects suffering from a specific disease or disorder, and subjects suspected of suffering from a specific disease or disorder are not necessarily two distinct groups.
  • the methods are directed to treating subjects having cancer.
  • the methods embrace treatment of adult tumors/cancers and pediatric tumors/cancers.
  • the cancers may be vascularized, or not yet substantially vascularized, or non-vascularized tumors.
  • the cancer is a lymphoid malignancy.
  • the lymphoid malignancy is peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia/lymphoma (ALL), or cutaneous T-cell lymphoma.
  • methods of the present disclosure entail treatment of subjects having cell proliferative diseases or disorders of the hematological system.
  • the methods are directed to treating subjects having an inflammatory disease or disorder.
  • the inflammatory disease or disorder is inflammatory bowel disease, myocarditis, endometriosis, atherosclerosis, an allergic disease or disorder, or an autoimmune disease or disorder.
  • the allergic disease or disorder is asthma or pollinosis.
  • the autoimmune disease is noninfectious meningitis, autoimmune encephalitis, transverse myelitis, or acute disseminated encephalomyelitis.
  • Compounds of formula (I) may be administered to a cancer patient as a monotherapy or by way of combination therapy.
  • Therapy may be "front/first-line", i.e., as an initial treatment in patients who have undergone no prior anti-cancer treatment regimens, either alone or in combination with other treatments; or "second-line”, as a treatment in patients who have undergone a prior anti-cancer treatment regimen, either alone or in combination with other treatments; or as “third-line”, “fourth-line”, etc. treatments, either alone or in combination with other treatments.
  • Therapy may also be given to patients who have had previous treatments which were unsuccessful or partially successful but who became unresponsive or intolerant to the particular treatment.
  • the compounds may be administered to a patient who has received another therapy, such as chemotherapy, radioimmunotherapy, surgical therapy, immunotherapy, radiation therapy, targeted therapy or any combination thereof.
  • another therapy such as chemotherapy, radioimmunotherapy, surgical therapy, immunotherapy, radiation therapy, targeted therapy or any combination thereof.
  • the methods of the present disclosure may entail administration of a compound of formula (I) or a pharmaceutical composition thereof to the patient in a single dose or in multiple doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, or more doses).
  • the frequency of administration may range from once a day up to about once every eight weeks.
  • the frequency of administration ranges from about once a day for 1, 2, 3, 4, 5, or 6 weeks, and in other embodiments entails at least one 28-day cycle which includes daily administration for 3 weeks (21 days) followed by a 7-day “off” period.
  • the compound may be dosed twice a day (BID) over the course of two and a half days (for a total of 5 doses) or once a day (QD) over the course of two days (for a total of 2 doses).
  • the compound may be dosed once a day (QD) over the course of 5 days.
  • the compounds of formula (I) and their pharmaceutically acceptable salts and stereoisomers may be used in combination or concurrently with at least one other active agent, e.g., anti-cancer agent or regimen, in treating cancer.
  • active agent e.g., anti-cancer agent or regimen
  • the terms “in combination” and “concurrently” in this context mean that the agents are co-administered, which includes substantially contemporaneous administration, by way of the same or separate dosage forms, and by the same or different modes of administration, or sequentially, e.g., as part of the same treatment regimen, or by way of successive treatment regimens.
  • the first of the two compounds is in some cases still detectable at effective concentrations at the site of treatment.
  • the sequence and time interval may be determined such that they can act together (e.g., synergistically) to provide an increased benefit than if they were administered otherwise.
  • the therapeutics may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they may be administered sufficiently close in time so as to provide the desired therapeutic effect, which may be in a synergistic fashion.
  • the terms are not limited to the administration of the active agents at exactly the same time.
  • the treatment regimen may include administration of a compound of formula (I) in combination with one or more additional therapeutics known for use in treating cancer.
  • the dosage of the additional therapeutic may be the same or even lower than known or recommended doses.
  • Anti-cancer agents that may be suitable for use in combination with the compounds are known in the art. See, e.g., U.S. Patent 9,101,622 (Section 5.2 thereof) and U.S. Patent 9,345,705 B2 (Columns 12-18 thereof).
  • additional anti-cancer agents and treatment regimens include radiation therapy, chemotherapeutics (e.g., mitotic inhibitors, angiogenesis inhibitors, anti-hormones, autophagy inhibitors, alkylating agents, intercalating antibiotics, growth factor inhibitors, anti-androgens, signal transduction pathway inhibitors, anti-microtubule agents, platinum coordination complexes, HDAC inhibitors, proteasome inhibitors, and topoisomerase inhibitors), immunomodulators, therapeutic antibodies (e.g., mono-specific and bispecific antibodies) and CAR-T therapy.
  • chemotherapeutics e.g., mitotic inhibitors, angiogenesis inhibitors, anti-hormones, autophagy inhibitors, alkylating agents, intercalating antibiotics, growth factor inhibitors, anti-androgens, signal transduction pathway inhibitors, anti-microtubule agents, platinum coordination complexes, HDAC inhibitors, proteasome inhibitors, and topoisomerase inhibitors
  • immunomodulators e.g., mono
  • a compound of formula (I) and the additional (e.g., anticancer) therapeutic may be administered less than 5 minutes apart, less than 30 minutes apart, less than 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours part.
  • additional (e.g., anticancer) therapeutic may be administered less than
  • the two or more (e.g., anticancer) therapeutics may be administered within the same patient visit.
  • the active components of the combination are not administered in the same pharmaceutical composition, it is understood that they can be administered in any order to a subject in need thereof.
  • a compound of the present disclosure can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of the additional therapeutic, to a subject in need thereof.
  • the therapeutics are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, no more than 24 hours apart or no more than 48 hours apart.
  • the (e.g., anticancer) therapeutics are administered within the same office visit.
  • the combination anticancer therapeutics may be administered at 1 minute to 24 hours apart.
  • a compound of formula (I) and the additional anti-cancer agent or therapeutic are cyclically administered. Cycling therapy involves the administration of one anticancer therapeutic for a period of time, followed by the administration of a second anti-cancer therapeutic for a period of time and repeating this sequential administration, i.e., the cycle, in order to reduce the development of resistance to one or both of the anticancer therapeutics, to avoid or reduce the side effects of one or both of the anticancer therapeutics, and/or to improve the efficacy of the therapies.
  • cycling therapy involves the administration of a first anticancer therapeutic for a period of time, followed by the administration of a second anticancer therapeutic for a period of time, optionally, followed by the administration of a third anticancer therapeutic for a period of time and so forth, and repeating this sequential administration, i.e., the cycle in order to reduce the development of resistance to one of the anticancer therapeutics, to avoid or reduce the side effects of one of the anticancer therapeutics, and/or to improve the efficacy of the anticancer therapeutics.
  • the compounds of the present disclosure may be used in combination with other anti-cancer agents, examples of which include Etoposide (e.g., lymphomas, and non-lymphocytic leukemia), Vincristine (e.g., leukemia), Daunorubicin (e.g., acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma), Rituximab (e.g., non-Hodgkin's lymphoma), Alemtuzumab (e.g., chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma), Bortezomib (e.g., multiple myeloma and mantle cell lymphoma), Pegaspargase (e.g., acute lymphoblastic leukemia), Keytru
  • Etoposide e
  • the additional anti-cancer agent is an enhancer of zeste homolog 2 (EZH2) inhibitor, examples of which include tazemetostat, GSK126, lirametostat (CPI-1205), CPI-0209, PF-06821497, SHR2554, HH2853, valemetostat (DS3201), MAK-683, and FTX-6058.
  • EZH2 enhancer of zeste homolog 2
  • reaction mixture was cooled to 15°C, diluted with H2O (1000 mL), extracted with EtOAc (1000 mL x 2), the combined organic phase was washed with brine (1000 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo.
  • tert-Butyl4,4-difluoro-3-methyl-5-[3-(p-tolylsulfonyloxy)propyl]piperidine-1- carboxylate [00171] To a solution of tert-butyl 4,4-difluoro-3-(3-hydroxypropyl)-5-methyl-piperidine-1- carboxylate (6.6 g, 22.50 mmol, 1 eq) in DCM (70 mL) were added TEA (4.55 g, 45.00 mmol, 6.26 mL, 2 eq) and TsCl (4.29 g, 22.50 mmol, 1 eq) at 15°C.
  • reaction mixture was then stirred at 60°C for 12 hr.
  • the reaction mixture (combined with another batch with 60 mg scale) was treated with H2O (10 mL) and extracted with EtOAc (10 mL x 3), the combined organic phase was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuo.
  • reaction mixture was then stirred at 15°C for 12 hr.
  • the reaction mixture (combined with another batch with 30 mg scale) was treated with H 2 O (2 mL), then the suspension was filtered and the solid was collected and dried in vacuo.
  • reaction mixture was then stirred at 80°C for 12 hr.
  • the reaction mixture was concentrated in vacuo to give a residue which was purified by prep-HPLC (column: Phenomenex C1875 * 30 mm * 3 ⁇ m; mobile phase: [water (NH 4 HCO 3 )-ACN]; B%: 45%-75%, 8 min) to give the title compound as a white solid (15 mg, 25.84 Pmol, 12% yield, 97% purity).
  • Example 2 Synthesis of 2-(((1 3 R,1 5 S)-2 5 -chloro-1 4 ,1 4 -difluoro-1 5 ,4 1 -dimethyl-4 2 -oxo- 4 1 ,4 2 -dihydro-5-oxa-3-aza-4(6,8)-quinolina-2(2,4)-pyrimidina-1(1,3)-piperidinacyclooctaphane- 4 3 -yl)oxy)-N-methylacetamide (5)
  • the mixture was stirred at 60°C for 12 hr.
  • the reaction mixture (combined with another batch with 30 mg scale) was cooled to 20°C and added water (2 mL).
  • the mixture was filtered and the filter cake was washed with water (5 mL), then the filter cake was dried in vacuo.
  • the mixture was filtered and the filter cake was dried in vacuo to give the title compound as a white solid (130 mg).
  • reaction mixture was then stirred at 15°C for 12 hr.
  • tert-Butyl 3-(2-benzyloxyethoxy)-5-methyl-piperidine-1-carboxylate [00203] To a solution of tert-butyl-3-hydroxy-5-methyl-piperidine-1-carboxylate (10 g, 46.45 mmol, 1 eq) in DMF (100 mL) was added NaH (3.72 g, 92.90 mmol, 60% purity, 2 eq) in portions at 0°C under N 2 .
  • tert-Butyl 3-(2-hydroxyethoxy)-5-methylpiperidine-1-carboxylate To a solution of tert-butyl 3-(2-benzyloxyethoxy)-5-methyl-piperidine-1-carboxylate (4.2 g, 12.02 mmol, 1 eq) in MeOH (50 mL) was added Pd/C (2 g, 10% purity) under N2. The suspension was degassed under vacuum and purged several times with H 2 . The mixture was stirred under H2 (50 psi) at 60°C for 12 hr.
  • tert-Butyl 3-methyl-5-[2-(p-tolylsulfonyloxy)ethoxy]piperidine-1-carboxylate [00207] To a mixture of tert-butyl 3-(2-hydroxyethoxy)-5-methyl-piperidine-1-carboxylate (3.3 g, 12.72 mmol, 1 eq) in DCM (30 mL) was added DMAP (155.45 mg, 1.27 mmol, 0.1 eq) and TEA (1.42 g, 14.00 mmol, 1.95 mL, 1.1 eq).
  • TsCl (2.67 g, 14.00 mmol, 1.1 eq) was added into the mixture at 0°C under N 2 .
  • the mixture was stirred at 15°C for 12 hr.
  • the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (80 mL x 3).
  • the combined organic phase was washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuo.
  • the mixture was stirred at 60°C for 3 hr.
  • the mixture was cooled to 20°C and water (3 mL) was added which caused a precipitate to form.
  • the filter cake was dried in vacuo to give the title compound as a yellow solid (350 mg, 548.69 Pmol, 67% yield, 86% purity).
  • the mixture was stirred at 20°C for 12 hr.
  • the reaction mixture was purified by flash silica gel chromatography (Silica Flash Column, Eluent of 10 ⁇ 100% EtOH/Ethyl acetate) to give ⁇ 300 mg of crude product.
  • the mixture was stirred at 80°C for 12 hr.
  • the mixture was filtered and the filtrate was purified directly without workup.
  • the filtrate was purified by p-HPLC (column: Waters XbridgeTM BEH C18100 * 30 mm * 10 ⁇ m; mobile phase: [water (NH4HCO3)-ACN]; B%: 40%-60%, 8 min) to give the title compound as a yellow solid (21 mg, 37.48 ⁇ mol, 12% yield, 94% purity).
  • Example 4 Synthesis of 2-(((1 3 S,1 5 R)-2 5 -chloro-1 5 ,4 1 -dimethyl-4 2 -oxo-4 1 ,4 2 -dihydro- 5,8-dioxa-3-aza-4(6,8)-quinolina-2(2,4)-pyrimidina-1(1,3)-piperidinacyclooctaphane-4 3 -yl)oxy)- N-methylacetamide (7) [00235] tert-Butyl (3R,5S)-3-methyl-5-[2-[[1-methyl-3-[2-(methylamino)-2-oxo-ethoxy]-6- nitro-2-oxo-8-quinolyl]oxy]ethoxy]piperidine-1-carboxylate [00236] To a solution of 2-[(8-hydroxy-1-methyl-6-nitro-2-oxo-3-quinolyl)oxy]-N-methyl- acetamide (200 mg, 650.92 P
  • the mixture was stirred at 60°C for 3 hr.
  • the mixture (combined with another batch with 50 mg scale) was cooled to 20°C and ⁇ 3 mL of water was added. A precipitate was occurred.
  • reaction mixture was stirred at 25°C for 2 hr.
  • the reaction mixture (combined with another batch with 500 mg scale) was treated with water (20 mL), then extracted with EtOAc (25 mL x 3).
  • the combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by prep-HPLC (column: Welch Xtimate® C18 180*70mm*10 ⁇ m;mobile phase: [water(NH4HCO3)-ACN];B%: 50%-80%,15min) to give the title compound as a white solid (1 g, 1.82 mmol, 66% yield, 99% purity).
  • tert-butyl (3S,5R)-3-(3-((6-(benzylamino)-3-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)oxy)propyl)-4,4-difluoro-5-methylpiperidine-1-carboxylate (1 g, 1.84 mmol, 1 eq) in THF (10 mL) was added Pd/C (300 mg, 10% purity) under Ar.
  • the suspension was degassed under vacuum and purged with Hz several times.
  • the reaction mixture was stirred under H? (15 psi) at 25°C for 12 hr.
  • the reaction mixture was filtered and the filtrate was concentrated in vacuo to give the title compound as a brown solid (800 mg, 1.60 mmol, 87% yield, 91 % purity).
  • reaction mixture was stirred at 25°C for 2 hr.
  • the reaction mixture was treated with water (8 mL), then the suspension was filtered.
  • the reaction mixture was stirred at 80°C for 12 hr.
  • the reaction mixture was treated with water (30 mL), then the suspension was filtered to give a residue.
  • the reaction mixture was stirred at 80°C for 12 hr.
  • the rection mixture was treated with water and the suspension was filtered.
  • the solid was purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30mm*10 ⁇ m;mobile phase: [water(NH 4 HCO 3 )-ACN];B%: 60%-90%,8min) to give the title compound as a white solid (30 mg, 53.90 ⁇ mol, 17% yield, 99% purity).
  • reaction mixture was stirred at 25°C for 2 hr.
  • the reaction mixture (combined with another batch with the same scale) was treated with water (20 mL), then extracted with EtOAc (25 mL x 3).
  • the combined organic phase was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by prep-HPLC (column: Welch Xtimate® C18 180*70mm#10 ⁇ m;mobile phase: [water(NH4HCO3)-ACN];B%: 50%-80%,15min) to give the title compound as a white solid (850 mg, 1.51 mmol, 59% yield, 97% purity).
  • reaction mixture was stirred at 80°C for 12 hr.
  • the reaction mixture was then treated with water (30 mL).
  • the reaction mixture was stirred at 80°C for 12 hr under N2.
  • the rection mixture was treated with water and the suspension was fitlered.
  • the solid was purified by prep-HPLC (column: Waters XbridgeTM Prep OBD C18 150*40mm*10 ⁇ m;mobile phase: [water(NH4HCO3)-ACN];B%: 45%-75%,8min) to give the title compound as a white solid (65 mg, 115.60 ⁇ mol, 36% yield, 98% purity).
  • Example 8 Synthesis of (FJ?,l 5 5)-2 5 -chloro-l 4 .r 4 -difluoro-l ⁇ 4 I .4 3 -trimethyl-4 2 ,4 3 - dihydro-4 t H-5-oxa-3-aza-4(6.4')-benzord]imidazola-2(2,4)-pyrimidina-l(1.3)- piperidinacyclooctaphan-4 2 -one (30)
  • reaction mixture was stirred at 15°C for 2 hr.
  • the reaction mixture (combined with 10 mg scale and 30 mg scale) was filtered and the filtrate was concentrated in vacuo to give a residue which was purified by p-HPLC (column: Waters XbridgeTM Prep OBD Cl 8 150*40mm*10 ⁇ m;mobile phase: [water(NH4HCO3) ⁇ ACN];B%: 50%-80%,8min) to give the title compound as a white solid (20 mg, 41.59 umol, 99% yield, 99% purity).
  • the reaction mixture was stirred at 20°C for 12 hr under N2 atmosphere. Water (30 mL) was added to the reaction mixture and the pink solid was filtered. The filter cake was dried under reduced pressure and then washed with EtOAc (40 mL). The solid was filtered and the filter cake was dried under reduced pressure to give the title compound as a pink solid (4 g, 9.70 mmol, 57% yield).
  • reaction mixture was stirred at 80 c C for 3 hr under N2 atmosphere.
  • the reaction mixture was concentrated under reduced, pressure to give a residue (combined with other 2 batches) which was purified by prep-HPLC (column: Waters XbridgeTM Prep OBD C18 150*40 mm*10 gm; mobile phase: [H2O(10mM NH4HCO.r)-ACN]; gradient: 35% - 60% B over 8.0 min) to give 80 mg of product.
  • the product (80 mg) was further purified by SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm* 10pm); mobile phase: [CCh-MeOH(0.
  • the reaction mixture was stirred at 25°C for 12 hr.
  • the reaction mixture (combined with other 4 batches with the same scale) was concentrated in vacuo and the residue was triturated with water (1 L) at 25°C for 30 min and filtered.
  • the solution was filtered and the filter cake was dried to give the title compound as a yellow solid (500 g, 95% purity, 68% yield).
  • the reaction mixture was degassed and purged with N2 for 5 min.
  • BrettPhos (2.67 g, 4.98 mmol, 0.04 eq) and BrettPhos Pd G3 (2.26 g, 2.49 mmol, 0.02 eq) were added to the reaction mixture which was stirred at 80°C for 2 hr under N 2 .
  • the reaction mixture (combined with another batch of the same scale) was quenched with sat. aq. NH4Cl (50 mL), filtered, dried with anhydrous Na2SO4, and filtered.
  • the residue was treated with 4N HCl (150 mL) and stirred at 40°C for 30 min.
  • the filter cake was triturated with EtOAc (150 mL) at 15°C for 30 min to give the title compound as a white solid (44 g, 158.49 mmol, 77% yield, 97% purity).
  • tert-Butyl (7-hydroxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)carbamate [00306] To a solution of 5-(benzylamino)-7-hydroxy-1-methyl-1,3-dihydro-2H- benzo[d]imidazol-2-one (15 g, 55.70 mmol, 1 eq) in MeOH (300 mL) was added Pd/C (5 g, 10% purity) under Ar. The suspension was degassed and purged with H23 times. The reaction mixture was stirred under H2 (50 psi) at 50°C for 12 hr.
  • tert-Butyl (7-(2-chloroethoxy)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)carbamate [00308] To a solution of tert-butyl (7-hydroxy-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)carbamate (10.00 g, 35.80 mmol, 1 eq) and 2-chloroethyl 4- methylbenzenesulfonate (8.40 g, 35.80 mmol, 1 eq) in ACN (20 mL) and DMF (20 mL) was added K2CO3 (12.37 g, 89.51 mmol, 2.5 eq).
  • reaction mixture was stirred at 70°C for 12 hr under N 2 .
  • the reaction was quenched with water (100 mL) and then extracted with ethyl acetate (80 mL x 3).
  • the organic phase was separated and washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo.
  • reaction mixture was stirred at 100°C for 36 hr in a glove box.
  • the reaction mixture was concentrated in vacuo and water (50 mL) was added.
  • the mixture was extracted with ethyl acetate (35 mL x 3).
  • tert-butyl (3R,5S)-3-(2-((6-(benzylamino)-3-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)oxy)ethoxy)-5-methylpiperidine-1-carboxylate (1 g, 1.96 mmol, 1 eq) in THF (20 mL) was added Pd/C (400 mg, 10% purity) under Ar.
  • the reaction mixture was stirred at 25°C for 2 hr.
  • the reaction mixture was treated with water (25 mL) and the precipitate was filtered.
  • the solid filtered and dried to give the title compound as a white solid (0.7 g, 1.15 mmol, 54% yield, 93% purity).
  • reaction mixture was stirred at 80°C for 12 hr.
  • the reaction mixture was filtered and residue was purified by prep-HPLC (column: Phenomenex C18 80*40mm*3 ⁇ m;mobile phase: [water(NH 4 HCO 3 )-ACN];B%: 25%-55%,8min) to give the title compound as a white solid (50 mg, 95.74 ⁇ mol, 22% yield, 99% purity).
  • reaction mixture was stirred at 80°C for 12 hr, then cooled to 25°C and purified by prep-HPLC (column: Waters XbridgeTM BEH C18100 *30 mm*10 ⁇ m;mobile phase: [water(NH 4 HCO 3 )-ACN];B%: 40%-70%,8min) to give the title compound as a white solid (20 mg, 38.30 ⁇ mol, 18% yield, 96% purity).
  • Example 13 Synthesis of (1 3 R,1 5 S)-2 5 -chloro-4 1 -(3-hydroxy-3-methylbutyl)-1 5 ,4 3 - dimethyl-4 2 ,4 3 -dihydro-4 1 H-5-oxa-3,8-diaza-4(6,4)-benzo[d]imidazola-2(2,4)-pyrimidina-1(1,3)- piperidinacyclooctaphan-4 2 -one (16) [00345] tert-Butyl (5-methylpyridin-3-yl)carbamate [00346] To a solution of 5-methylpyridin-3-amine (12.5 g, 115.59 mmol, 1 eq) in THF (100 mL) at 25°C was added NaHMDS (1 M, 254.30 mL, 2.2 eq) and the reaction mixture was stirred for 30 min.
  • Boc2O (26.99 g, 123.68 mmol, 28.41 mL, 1.07 eq) in THF (25 mL) was added and the reaction mixture was stirred at 25°C for 12 hr.
  • the reaction mixture (combined with another batch of the same scale) was quenched with water (50 mL), and treated with 0.2 M HCl (300 mL). The mixture was extracted with EtOAc (500 mL x 3).
  • tert-Butyl (5-methylpiperidin-3-yl)carbamate [00348] To a solution of tert-butyl (5-methylpyridin-3-yl)carbamate (17 g, 81.63 mmol, 1 eq) in AcOH (340 mL) were added Pd/C (14 g, 10% purity) and PtO 2 (1.85 g, 8.16 mmol, 0.1 eq) under Ar. The suspension was degassed under vacuum and purged with H 2 several times. The reaction mixture was stirred under H2 (3 Mpa) at 80°C for 12 hr. The reaction mixture was filtered, and the filter cake was washed with MeOH (500 mL x 3).
  • tert-Butyl (1-benzyl-5-methylpiperidin-3-yl)carbamate [00350] A mixture of tert-butyl (5-methylpiperidin-3-yl)carbamate (10 g, 46.66 mmol, 1 eq), benzaldehyde (5.94 g, 56.00 mmol, 5.66 mL, 1.2 eq) and AcOH (1.40 g, 23.33 mmol, 1.33 mL, 0.5 eq) in DMF (250 mL) was stirred at 15°C for 2 hr.
  • tert-Butyl (l-benzyl-5-methylpiperidin-3-yl)carbamate (5 g, 16.42 mmol, I eq) was separated by SFC (column: REGIS (s,s) WHELK-01 (250mm*50mm, 10 ⁇ m);mobile phase: [Hexane-IPA];B%: 5%-5%,3.5min) to give tert-butyl ((3A,5S)-l-benzyl-5-methylpiperidin-3- yl)carbamate as white solid (1.8 g, 5.79 mmol, 98% yield, 98% purity) and tert-butyl ((37,57?)-!- benzyl-5-methylpiperidin-3-yl)carbamate as a white solid (1.8 g, 5.62 mmol, 95% yield, 95% purity).
  • reaction mixture was stirred at 80°C for 12 hr under N 2 atmosphere.
  • the reaction mixture was filtered and the filtrate was purified by prep- HPLC (column: Waters XbridgeTM BEH C18 100*30mm*10 ⁇ m; mobile phase: [water(NH4HCO3)-ACN];B%: 35%-55%,8min) to give the title compound as a white solid (23 mg, 44.12 ⁇ PRO ⁇ 7% yield, 99% purity).
  • the suspension was degassed under vacuum and purged with H2 several times.
  • the reaction mixture was stirred under H2 (15 psi) at 25°C for 12 hr.
  • the reaction mixture was filtered and the filtrate was concentrated in vacuo to give the title compound as a white solid (0.8 g, crude).
  • reaction mixture was stirred at 80°C for 12 hr under N? atmosphere.
  • the reaction mixture was filtered and the filtrate was purified by prep-HPLC(coiurnn: Waters XbridgeTM Prep OBD Cl 8 150*40mm*10
  • 6-(Benzylamino)-8-hydroxy-1-methyl-1,4-dihydroquinoxaline-2,3-dione [00380] 6-(benzylamino)-8-methoxy-1-methyl-1,4-dihydroquinoxaline-2,3-dione (20 g, 64.24 mmol, 1 eq) was dissolved in DCM (400 mL) and cooled to -70°C. BBr 3 (80.47 g, 321.20 mmol, 30.95 mL, 5 eq) in DCM (50 mL) was added dropwise to the reaction mixture under N 2 . The reaction mixture was warmed to 40°C and stirred for 12 hr.
  • the suspension was degassed under vacuum and purged with H 2 3 times.
  • the reaction mixture was stirred under H 2 (15 psi) at 25°C for 12 hr.
  • the reaction mixture (combined with another batch of the same scale) was filtered through a pad of Celite® and the filtrate was concentrated in vacuo to give the title compound as a red solid (800 mg, crude).
  • Example 16 Synthesis of (1 3 R,1 5 S)-2 5 -chloro-1 4 ,1 4 -difluoro-4 1 -(((1R,3R)-3- hydroxycyclobutyl)methyl)-1 5 ,4 4 -dimethyl-4 1 ,4 2 ,4 3 ,4 4 -tetrahydro-5-oxa-3-aza-4(7,5)- quinoxalina-2(2,4)-pyrimidina-1(1,3)-piperidinacyclooctaphane-4 2 ,4 3 -dione (19-1) and (1 3 R,1 5 S)- 2 5 -chloro-1 4 ,1 4 -difluoro-4 1 -((( -3-hydroxycyclobutyl) methyl)-1 5 ,4 4 -dimethyl-4 1 ,4 2 ,4 3 ,4 4 - tetrahydro-5-oxa-3-aza-4(7,5)-quinoxalina-2
  • reaction mixture was stirred at 0°C for 30 minutes and then 2- bromoethoxymethylbenzene (13.35 g, 62.08 mmol, 9.82 mL, 1.2 eq) was added.
  • the reaction mixture was heated to 90°C and stirred for 12 hr under N 2 .
  • the reaction mixture was quenched slowly with sat. NH 4 Cl (100 mL) and then extracted with ethyl acetate (150 mL x 2).
  • the combined organic phase was washed with brine (200 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo.
  • tert-Butyl (3S,5R)-4,4-difluoro-3-(2-hydroxyethoxy)-5-methylpiperidine-1-carboxylate [00422] To a solution of tert-butyl 3-(2-benzyloxyethoxy)-4,4-difluoro-5-methyl-piperidine-1- carboxylate (5.70 g, 14.79 mmol, 1 eq) in MeOH (60 mL) was added Pd/C (2 g, 10% purity) under Ar. The suspension was degassed under vacuum and purged with H 2 several times. The reaction mixture was stirred under H 2 (50 psi) at 60°C for 12 hr.
  • tert-Butyl (3R,5S)-4,4-difluoro-3-methyl-5-(2-(tosyloxy)ethoxy)piperidine-1- carboxylate [00424] To a solution of tert-butyl 4,4-difluoro-3-(2-hydroxyethoxy)-5-methyl-piperidine-1- carboxylate (4.3 g, 14.56 mmol, 1 eq) in DCM (40 mL) was added DMAP (177.88 mg, 1.46 mmol, 0.1 eq) and TEA (2.95 g, 29.12 mmol, 4.05 mL, 2 eq).4-methylbenzenesulfonyl chloride (4.16 g, 21.84 mmol, 1.5 eq) was then added at 15°C.
  • reaction mixture was stirred at 15°C for 12 hr.
  • the reaction mixture was treated with water (50 mL), then extracted with EtOAc (50 mL x 3).
  • the combined organic phase was washed with brine (80 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo.
  • the reaction mixture was stirred at 70°C for 2 hr under N2.
  • the reaction mixture was poured into water and filtered.
  • the filter cake was washed with water and dried in vacuo to give the title compound as a yellow solid (800 mg, 1.46 mmol, 49% yield).
  • the suspension was degassed under vacuum and purged with H 2 several times.
  • the reaction mixture was stirred under H 2 (15 psi) at 20°C for 24 hr.
  • the reaction mixture was filtered, and then concentrated under reduced pressure to give the title compound as a yellow solid (600 mg, crude).
  • reaction mixture was stirred at 80°C for 12 hr under N2 atmosphere.
  • the reaction mixture was concentrated in vacuo and the residue was purified by p-HPLC (column: WatersTM Abridge BEH C18 100*30 mm* 10 ⁇ m; mobile phase: [HzO(10 mM NH4HCOs)-ACN]; gradient: 35% - 65% B over 8.0 min) to give the title compound as a white solid (50 mg, 98.9% purity).
  • reaction mixture was stirred at 80°C for 12 hr.
  • the reaction mixture (combined with another batch with 30 mg scale) was concentrated in vacuo and the residue was purified by prep-HPLC (column: Waters’TM Xbridge BEH C18 100*30mm 5pm, mobile phase: [H2O(10mM NH4HCO3)-ACN];gradient:33%-59% B over 8.0 min) to give the title compound as a white solid (25 mg, 99% purity).
  • reaction mixture (combined with another batch with 1 g scale) was poured into water (200 mL) and filtered. The filter cake was washed with water (100 mL) and dried in vacuo. The residue was triturated PE/EtOAc (20 mL, 3:1) at 15°C for 30 minutes. The mixture was filtered and the filter cake was dried in vacuo to give the title compound as a yellow solid (4.3 g, 66% yield).
  • reaction mixture was stirred at 15°C for 2 hr.
  • the reaction mixture (combined with another batch with 1 g scale) was concentrated in vacuo and water (20 mL) was added.
  • the mixture was filtered and the filter cake was dried in vacuo to give the title compound as a yellow solid (2.8 g, 68% yield).
  • the reaction mixture was stirred at 15°C for 2 hr under N2.
  • the reaction mixture (combined with another batch with 0.8 g scale) was poured into water (100 mL), filtered, and washed with water (50 mL).
  • the filter cake was dried in vacuo and the residue was triturated with MeOH (10 mL) at 15°C for 10 minutes.
  • the mixture was filtered, and the filter cake was dried in vacuo to give the title compound as a yellow solid (2 g, 74% yield).
  • reaction mixture was stirred at 80°C for 10 hr under N2.
  • the reaction mixture was concentrated in vacuo and the residue was purified by prep-HPLC (column: WatersTM Abridge BEH Cl 8 250*50mm*10 ⁇ m; mobile phase: [H 2 O(10m.M NFHHCCh)- ACN];gradient:30%-60% B over 10 min) to give the title compound as a white solid (350 mg, 640.45 ⁇ mol, 33% yield).
  • HiBiT protocol [00475] DC50 (concentration to reach 50% degradation) values were determined from a cellular degradation assay (HiBiT, PromegaTM) in Su-DHL-4 cells (Table 1). Endogenous BCL6 was tagged with the 11-amino acid SmBiT through CRISPR/Cas9 gene editing and single cell clone selection. After 24 hr of compound treatment, cells were lysed and incubated with LgBiT protein to reconstitute intact nanoluciferase. Substrate was then added and relative luciferase units were measured. Degradation levels for each treatment were taken as a percentage compared to the control, 100% DMSO (Prism). Table 1. Degradation activity of compounds 131

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes de traitement de maladies et de troubles qui impliquent une activité aberrante du lymphome à cellules B 6 (BCL6).
PCT/US2023/029714 2022-08-09 2023-08-08 Agents de dégradation de bcl6 macrocycliques WO2024035688A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263396381P 2022-08-09 2022-08-09
US63/396,381 2022-08-09
US202263432580P 2022-12-14 2022-12-14
US63/432,580 2022-12-14
US202363465584P 2023-05-11 2023-05-11
US63/465,584 2023-05-11

Publications (1)

Publication Number Publication Date
WO2024035688A1 true WO2024035688A1 (fr) 2024-02-15

Family

ID=89852399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/029714 WO2024035688A1 (fr) 2022-08-09 2023-08-08 Agents de dégradation de bcl6 macrocycliques

Country Status (1)

Country Link
WO (1) WO2024035688A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338464B2 (en) * 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
US20190000860A1 (en) * 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20200071297A1 (en) * 2016-12-13 2020-03-05 Boehringer Ingelheim International Gmbh New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
US20210030740A1 (en) * 2019-07-30 2021-02-04 Northwestern University B cell lymphoma 6 protein (bcl6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338464B2 (en) * 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
US20190000860A1 (en) * 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20200071297A1 (en) * 2016-12-13 2020-03-05 Boehringer Ingelheim International Gmbh New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
US20210030740A1 (en) * 2019-07-30 2021-02-04 Northwestern University B cell lymphoma 6 protein (bcl6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

Similar Documents

Publication Publication Date Title
AU2024203058A1 (en) BRM targeting compounds and associated methods of use
CA2719876C (fr) Hydroxymethyl pyrrolidines en tant qu'agonistes de recepteur beta 3 adrenergique
CA2894298C (fr) Composes de dihydroisoquinolinone substitue
AU2024203200A1 (en) Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
US20230265116A1 (en) Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
TW201107325A (en) Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof
JP6908536B2 (ja) ムスカリンｍ２受容体の正のアロステリックモジュレーター
EP2420502A1 (fr) Dérivé de pyrrolopyridine condensé
US11981644B2 (en) Bicyclic 1,4-diazepanones and therapeutic uses thereof
AU2019382504A1 (en) Cyclic ureas
EP4284365A1 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
KR20210049895A (ko) 고 활성 sting 단백질 작용제 화합물
AU2022325137A1 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
CA3172498A1 (fr) Degradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procedes d'utilisation
EP3481823B1 (fr) Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitués en position 7, et leur utilisation
US20230023559A1 (en) Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
JP2022545314A (ja) プログラニュリンモジュレーターおよびその使用方法
WO2023139199A1 (fr) Composés et leur utilisation dans le traitement du cancer
WO2024035688A1 (fr) Agents de dégradation de bcl6 macrocycliques
WO2021065898A1 (fr) Dérivé d'azépane
TW202146398A (zh) 靶向ｒｎａ－結合蛋白質或ｒｎａ－修飾蛋白質之化合物
WO2024086094A1 (fr) Agents de dégradation de bcl6 à petites molécules contenant une alkylamine
CN117980290A (zh) 氰基吡啶和氰基嘧啶bcl6降解剂
WO2024026479A2 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024019995A1 (fr) Agents de dégradation de lymphome à cellules b 6 (bcl6) de quinoxalinedione et de pyrido [2, 3-bjpyrazine -2, 3-dione et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853274

Country of ref document: EP

Kind code of ref document: A1